Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW5282 and Golidocitinib in T-Cell Lymphoma
NCT07496229Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GW5282 in T-cell lymphoma (4 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 21 days and Complete Response Rate. Started Apr 2026; status: recruiting.
02
Drugs
GW5282
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT07496229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496229.